



## Epidiolex® (cannabidiol) – New and expanded indications

- On July 31, 2020, the [FDA approved](#) Greenwich Biosciences' [Epidiolex \(cannabidiol\)](#) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC) in patients 1 years of age and older.
  - Previously, Epidiolex was only approved for the treatment of seizures associated with LGS or DS in patients  $\geq 2$  years of age.
- The safety and effectiveness of Epidiolex for the treatment of seizures associated with LGS, DS, or TSC have been established in patients 1 year of age and older. The use of Epidiolex in these indications is supported by adequate and well-controlled studies in patients 2 years of age and older with LGS and DS and in patients 1 year of age and older with TSC.
- The effectiveness of Epidiolex for the treatment of seizures associated with TSC was demonstrated in a randomized, double-blind, placebo-controlled trial in 224 patients aged 1 to 65 years. The primary efficacy measure was the change in seizure frequency of TSC-associated seizures over the 16-week treatment period compared with baseline.
  - The median percentage change from baseline in the frequency of TSC-associated seizures was significantly greater for patients treated with Epidiolex vs. placebo (-43% vs. -20%;  $p < 0.01$ , respectively).
- The recommended dosage of Epidiolex for the treatment of seizures associated with LGS, DS or TSC is 2.5 mg/kg by mouth twice daily.
  - For LGS or DS, after one week, the dosage can be increased to a maintenance dosage of 5 mg/kg twice daily (10 mg/kg/day).
  - For TSC, the dose may be increased weekly in increments of 2.5 mg/kg twice daily as tolerated to a maintenance dosage of 12.5 mg/kg twice daily.
  - Refer to the Epidiolex prescribing information for further dosing instructions.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.